Financial Performance - The company's revenue for 2024 is reported at ¥536,595,592.03, a decrease of 5.26% compared to ¥566,399,208.58 in 2023[23]. - The net profit attributable to shareholders for 2024 is a loss of ¥27,591,132.24, representing a decline of 219.94% from a profit of ¥23,005,014.76 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is a loss of ¥28,216,624.07 for 2024, down 234.61% from ¥20,961,686.55 in 2023[23]. - The operating cash flow for 2024 is reported at -¥20,588,447.63, a decrease of 130.22% compared to ¥68,132,540.93 in 2023[23]. - The basic earnings per share for 2024 is -¥0.24, a decline of 220.00% from ¥0.20 in 2023[23]. - The total assets at the end of 2024 amount to ¥2,789,880,328.86, an increase of 13.98% from ¥2,447,740,699.18 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 are ¥923,137,679.57, a decrease of 3.11% from ¥952,749,525.16 at the end of 2023[23]. - The company reported a significant drop in weighted average return on equity to -2.94% in 2024 from 2.45% in 2023[23]. - The revenue after deducting certain amounts for 2024 is ¥532,568,105.18, compared to ¥565,501,718.58 in 2023[23]. - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years[23]. Operating Expenses and Costs - Operating expenses increased compared to the same period last year, mainly due to the expansion of the company's scale and the addition of personnel during the construction period of its subsidiary, leading to higher salary and operational costs[5]. - Financial expenses increased due to the capitalization of interest on convertible bonds and project-specific loans being converted to expenses[5]. - The gross profit margin for steroid raw material manufacturing was 19.67%, down 2.42% from the previous year[59]. - Direct materials accounted for 61.91% of total costs, an increase of 8.25% compared to the previous year[62]. - The net profit attributable to shareholders decreased, resulting in an overall loss due to increased operating costs and R&D expenses[54]. Research and Development - The company has increased its R&D investment to enhance industry technology barriers, resulting in a corresponding rise in R&D expenses[5]. - Research and development expenses increased by 34.08% to ¥51,083,365.27 compared to ¥38,098,898.41 in the previous year[66]. - The company established a dedicated R&D center to enhance innovation efficiency and reduce costs, leading to significant improvements in existing products[56]. - The company plans to enhance its high-end R&D platform and increase investment in new product development to improve product quality and market competitiveness[47]. - The company is focusing on three strategic directions: technological iteration, capacity expansion, and market deepening to strengthen its core position in the steroid drug industry[46]. Market and Industry Trends - The global steroid drug market is experiencing rapid growth, leading to intensified competition and pressure on profit margins, which the company aims to address through continuous R&D investment and strategic collaborations[7]. - The global steroid drug market has reached hundreds of billions of dollars, with expectations for continued high growth due to widespread applications in treating various diseases[35]. - The domestic steroid drug market is also experiencing significant growth, driven by an expanding pharmaceutical market and increasing demand for treatments related to endocrine disorders and inflammatory diseases[35]. - The company operates in the pharmaceutical manufacturing sector, focusing on the research, production, and sales of steroid drug raw materials[32]. Corporate Governance - The company has established a mature governance structure with a separation of powers among the shareholders' meeting, board of directors, supervisory board, and management team[88]. - The company emphasizes compliance and risk management, planning to enhance its operational system and processes through digital transformation initiatives[88]. - The company held 1 annual shareholders' meeting and 3 temporary shareholders' meetings during the reporting period, ensuring compliance with relevant regulations[94]. - The board of directors held 12 meetings, with a composition of 7 members including 3 independent directors, adhering to legal and regulatory requirements[96]. - The company has established a performance evaluation and incentive mechanism for senior management, linking their compensation to the company's operational performance[99]. Environmental Responsibility - The company strictly adheres to environmental protection policies and has obtained necessary environmental impact assessments and permits for its projects[143]. - The company has implemented a wastewater treatment system that follows the principle of "rainwater and sewage separation" and ensures compliance with discharge standards[147]. - The company utilizes a comprehensive air pollution control process including alkaline spraying, water spraying, and regenerative thermal oxidation (RTO) for emissions[147]. - The company has established a complete hazardous waste management system, including a dedicated storage area and compliance with relevant regulations[147]. - The company reported no exceedances in pollutant emissions for major pollutants monitored[146]. Employee Management and Development - The total number of employees at the end of the reporting period is 817, with 157 in the parent company and 660 in major subsidiaries[130]. - The professional composition includes 428 production personnel, 17 sales personnel, 143 technical personnel, 16 financial personnel, and 213 administrative personnel[130]. - The company has established a comprehensive salary system and incentive mechanism to ensure employee interests, including basic salary and performance bonuses[131]. - The company emphasizes the output and contribution of research personnel, providing project incentive bonuses based on project completion[132]. - The company conducts a "Sailing Plan" talent development program to enhance employee capabilities and professional quality[133]. Strategic Initiatives - The company aims to enhance its competitive edge through technology, product, customer, and management advantages for long-term healthy development[6]. - The company is optimizing its product structure to meet the evolving demands of downstream steroid drug manufacturers, which may lead to higher costs and lower gross margins during the trial production phase[10]. - The company has established a market-driven marketing system to enhance its competitive edge throughout the product lifecycle[52]. - The company aims to build a comprehensive quality network covering R&D, production, and warehousing, with ongoing preparations for compliance checks and certifications[53]. - The company aims to enhance its core competitiveness through continuous technological innovation and product development, focusing on "technology leadership, capacity upgrading, and green transformation"[84].
共同药业(300966) - 2024 Q4 - 年度财报